An observational study in Atopic Dermatitis, Atopic Dermatitis (AD) and Atopic Dermatitis (Eczema), sponsored by Caja Costarricense de Seguro Social. Not yet recruiting at 1 site in Costa Rica. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Caja Costarricense de Seguro Social · Observational
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.
This is a national, multicenter, observational registry of patients with atopic dermatitis treated in dermatology referral centers in Costa Rica. The registry aims to document demographic characteristics, disease history, severity, comorbidities, treatment patterns, and longitudinal outcomes in patients receiving systemic immunosuppressants, biologic agents, or other advanced therapies in routine clinical practice.
Data will be collected prospectively and retrospectively from medical records and routine clinical assessments, including validated severity indices (e.g., EASI, SCORAD, DLQI), treatment exposure, adverse events, and therapeutic response over time. The registry will allow evaluation of real-world effectiveness, safety, and treatment persistence, as well as characterization of moderate-to-severe atopic dermatitis in the Costa Rican population.
This registry does not modify clinical management; all treatments are prescribed according to physician judgment and standard care.
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's planned enrollment of 50 is below the median of 150 across 237 observational studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Caja Costarricense de Seguro Social is the lead sponsor of 12 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population includes pediatric and adult patients with moderate-to-severe atopic dermatitis treated in dermatology referral centers in Costa Rica who require systemic immunomodulatory or biologic therapy. These patients represent individuals with more severe or refractory disease seen in specialized care settings, often with significant disease burden, chronic course, and impact on quality of life. The registry captures real-world clinical practice across participating centers and reflects the national population receiving advanced atopic dermatitis therapies.
Exclusion Criteria:
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Change in atopic dermatitis severity over time
Measured using validated clinical severity scales EASI (Eczema Area and Severity Index)
Time frame: 5 years
Change in atopic dermatitis severity over time
Measured using the validated clinical severity scale SCORAD (SCORing Atopic Dermatitis) from baseline through follow-up visits during routine care.
Time frame: 5 years
Treatment patterns in moderate-to-severe atopic dermatitis
Type and duration of systemic or advanced therapies prescribed in real-world practice during the observation period.
Time frame: 5 years
Patient-reported quality of life
Change in Dermatology Life Quality Index (DLQI) scores over time during treatment.
Time frame: 5 years
Plan to share: No — According to protocol
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Caja Costarricense de Seguro Social